Contineum Therapeutics, Inc. Operating Lease, Payments
Contineum Therapeutics, Inc. (CTNM) reported Operating Lease, Payments of $1.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-07-30
- Contineum Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $538.00K, a 42.33% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $1.33M, a 251.32% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $853.00K, a 576.98% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $378.00K.
- Contineum Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.99M, a 1476.98% increase from fiscal 2024.
- Contineum Therapeutics, Inc. operating lease, payments for fiscal 2024 was $126.00K, a 93.76% decline from fiscal 2023.
- Contineum Therapeutics, Inc. operating lease, payments for fiscal 2023 was $2.02M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.87M 10-Q · filed 2026-07-30 | $2.72M derived: sum of 3 quarters · filed 2026-07-30 | $3.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-05 | $2.18M derived: sum of 2 quarters · filed 2026-05-05 | $2.56M derived: sum of 3 quarters · filed 2026-05-05 | $2.94M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.23M derived: sum of 2 quarters · filed 2026-03-05 | $1.61M derived: sum of 3 quarters · filed 2026-07-30 | $1.99M 10-K · filed 2026-03-05 |
| 2025-09-30 | $378.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $756.00K derived: sum of 2 quarters · filed 2026-07-30 | $1.13M 10-Q · filed 2025-10-30 | $1.26M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $378.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $756.00K 10-Q · filed 2026-07-30 | $882.00K derived: sum of 3 quarters · filed 2026-07-30 | $882.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $378.00K 10-Q · filed 2026-05-05 | $504.00K derived: sum of 2 quarters · filed 2026-05-05 | $504.00K derived: sum of 3 quarters · filed 2026-05-05 | $504.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $126.00K derived: sum of 2 quarters · filed 2026-03-05 | $126.00K derived: sum of 3 quarters · filed 2026-03-05 | $126.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $2.02M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |